The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Association of semaglutide with risk of suicidal ideation in a real-world cohort
Open accessAbstract
Concerns over reports of suicidal ideation associated with semaglutide treatment, a glucagon-like peptide 1 receptor (GLP1R) agonist medication for type 2 diabetes (T2DM) and obesity, has led to investigations by European regulatory agencies. In this retrospective cohort study of electronic health records from the TriNetX Analytics Network, we aimed to assess the associations of semaglutide with suicidal ideation compared to non-GLP1R agonist anti-obesity or anti-diabetes medications. The hazard ratios (HRs) and 95% confidence intervals (CIs) of incident and recurrent suicidal ideation were calculated for the 6-month follow-up by comparing propensity score-matched patient groups. The study population included 240,618 patients with overweight or obesity who were prescribed semaglutide or non-GLP1R agonist anti-obesity medications, with the findings replicated in 1,589,855 patients with T2DM. In patients with overweight or obesity (mean age 50.1 years, 72.6% female), semaglutide compared with non-GLP1R agonist anti-obesity medications was associated with lower risk for incident (HR = 0.27, 95% CI = 0.200.32-0.600.36) and recurrent (HR = 0.44, 95% CI = 0.32-0.60) suicidal ideation, consistent across sex, age and ethnicity stratification. Similar findings were replicated in patients with T2DM (mean age 57.5 years, 49.2% female). Our findings do not support higher risks of suicidal ideation with semaglutide compared with non-GLP1R agonist anti-obesity or anti-diabetes medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in the retrospective cohort study using TriNetX Analytics Network electronic health records, semaglutide significantly lowered the risk of both new (HR, 0.27; 95% CI, 0.20 to 0.32) and recurrent (HR, 0.44; 95% CI, 0.32 to 0.60) suicidal ideation compared to non-GLP-1 RAs anti-obesity treatments [80].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas several observational studies have generated varied findings on of the effect of GLP-1 receptor agonists on the risk of suicidal ideation, self-harm, and suicide, which may be a result of methodological limitations in these studies.8 9 10 11 12 13”
From Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“and recurrent (HR, 0.44; 95% CI, 0.32 to 0.60) suicidal ideation compared to non-GLP-1 RAs anti-obesity treatments [80].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [80]
In the citing paper
“Among AOMs currently approved, tirzepatide 15 mg and semaglutide 2.4mg have the greatest efficacy (Figure 1).65,67,87”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Glucagon-like peptide 1 receptor (GLP1R) agonists initially developed as anti-diabetes medications are highly effective for weight loss 8,9 .”
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001952 · Cited by 318
Sam, A. H., Salem, V., & Ghatei, M. A. (2011) · Journal of Obesity · doi:10.1155/2011/432607 · Cited by 230
Worldwide suicide mortality trends (2000-2019): A joinpoint regression analysis
Ilić, M., & Ilić, I. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i8.1044 · Cited by 220
Castaneda, D., Popov, V. B., Wander, P., & Thompson, C. C. (2019) · Obesity Surgery · doi:10.1007/s11695-018-3493-4 · Cited by 186
The critical distinction between suicidal ideation and suicide attempts
Klonsky, E. D., Dixon‐Luinenburg, T., & May, A. M. (2021) · World Psychiatry · doi:10.1002/wps.20909 · Cited by 181
Cheung, B. M. Y., Cheung, T. T., & Samaranayake, N. R. (2013) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613489721 · Cited by 163
Research works printed but not linked: 2
- Findlay, S. Health policy brief: the FDA’s sentinel initiative. Health Affairs www.healthaffairs.org/do/10.1377/hpb20150604.936915/ (2015). · DOI
- John Mann, J. & Currier, D. Insights from Neurobiology of Suicidal Behavior (CRC Press, 2012).
Cited by
Sorted by citations
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Wang, L., Xu, R., Kaelber, D. C., & Berger, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21305 · Cited by 304
Self-citationMapping the effectiveness and risks of GLP-1 receptor agonists
Xie, Y., Choi, T., & Al-Aly, Z. (2025) · Nature Medicine · doi:10.1038/s41591-024-03412-w · Cited by 300
Ludwig, R. J., Anson, M., Zirpel, H., Thaçi, D., Olbrich, H., Bieber, K., Kridin, K., Dempfle, A., Curman, P., Zhao, S. S., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516126 · Cited by 299
Wang, W., Wang, Q., Qi, X., Gurney, M., Perry, G., Volkow, N. D., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14313 · Cited by 180
Self-citationThe benefits of GLP-1 drugs beyond obesity
Drucker, D. J. (2024) · Science · doi:10.1126/science.adn4128 · Cited by 172
Kornelius, E., Huang, J.-Y., Lo, S.-C., Huang, C.-N., & Yang, Y.-S. (2024) · Scientific Reports · doi:10.1038/s41598-024-75965-2 · Cited by 143
Wang, W. J., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Nature Communications · doi:10.1038/s41467-024-48780-6 · Cited by 138
Self-citationWang, L., Berger, N. A., Kaelber, D. C., & Xu, R. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.04.029 · Cited by 136
Self-citationGhusn, W., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100127 · Cited by 122
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Schoretsanitis, G., Weiler, S., Barbui, C., Raschi, E., & Gastaldon, C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23385 · Cited by 107
GLP-1 Receptor Agonist Use and Risk of Suicide Death
Ueda, P., Söderling, J., Wintzell, V., Svanström, H., Pazzagli, L., Eliasson, B., Melbye, M., Hviid, A., & Pasternak, B. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4369 · Cited by 103
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 110
Wadden, T. A., Brown, G. K., Egebjerg, C., Frenkel, O., Goldman, B., Kushner, R. F., McGowan, B., Overvad, M., & Fink-Jensen, A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4346 · Cited by 96
Zhou, J., Zheng, Y., Xu, B., Long, S., Zhu, L.-E., Liu, Y., Li, C., Zhang, Y., Liu, M., & Wu, X. (2024) · BMC Medicine · doi:10.1186/s12916-024-03274-6 · Cited by 88
Wang, W. Y., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02498-5 · Cited by 89
Self-citationGLP-1 and Its Analogs: Does Sex Matter?
Börchers, S., & Skibicka, K. P. (2024) · Endocrinology · doi:10.1210/endocr/bqae165 · Cited by 96
Giorgi, R. D., Koychev, I. G., Adler, A., Cowen, P. J., Harmer, C. J., Harrison, P. J., & Taquet, M. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102726 · Cited by 91
Giorgi, R. D., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A., Koychev, I. G., Upthegrove, R., Solmi, M., McCutcheon, R. A., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 92
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2718 · Cited by 72
Self-citationGuirguis, A., Chiappini, S., P, G. P., Vickers‐Smith, R., Harris, D. R., Corkery, J., Arillotta, D., Floresta, G., Martinotti, G., & Schifano, F. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.02.003 · Cited by 79
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 70
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
“…the retrospective cohort study using TriNetX Analytics Network electronic health records, semaglutide significantly lowered the risk of both new (HR, 0.27; 95% CI, 0.20 to 0.32) and recurrent (HR, 0.44; 95% CI, 0.32 to 0.60) suicidal ideation compared to non-GLP-1 RAs anti-obesity treatments [80].”
InfluentialRuggiero, R., Mascolo, A., Spezzaferri, A., Carpentieri, C., Torella, D., Sportiello, L., Rossi, F., Paolisso, G., & Capuano, A. (2024) · Pharmaceuticals · doi:10.3390/ph17020147 · Cited by 58
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., Rhee, T. G., Cao, B., Teopiz, K. M., Wong, S., Le, G. H., Ho, R., & Kwan, A. T. H. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.062 · Cited by 60
Wang, L., Wang, Q., Li, L., Kaelber, D. C., & Xu, R. (2025) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djae260 · Cited by 53
Self-citationStokar, J., & Szalat, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae173 · Cited by 53
Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes
Wang, L., Volkow, N. D., Kaelber, D. C., & Xu, R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26327 · Cited by 51
Self-citationEbrahimi, P., Batlle, J. C., Ayati, A., Maqsood, M. H., Long, C., Tarabanis, C., McGowan, N., Liebers, D. T., Laynor, G., Hosseini, K., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0091 · Cited by 51
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Herman, R. J., & Schmidt, H. D. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114565 · Cited by 54
Shapiro, S. B., Yin, H., Yu, O. H. Y., Rej, S., Suissa, S., & Azoulay, L. (2025) · BMJ · doi:10.1136/bmj-2024-080679 · Cited by 49
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Valenta, S. T., Nicastri, A., Perazza, F., Marcolini, F., Beghelli, V., Atti, A. R., & Petroni, M. L. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00331-y · Cited by 51
Hurtado, I., Robles, C., Peiró, S., García-Sempere, A., & Sanfélix-Gimeno, G. (2024) · Diabetologia · doi:10.1007/s00125-024-06243-z · Cited by 45
Muayad, J., Loya, A., Hussain, Z. S., Chauhan, M. Z., Alsoudi, A. F., De Francesco, T., & Ahmed, I. I. K. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2024.08.023 · Cited by 45
Cai, M., Choi, T., Xie, Y., & Al‐Aly, Z. (2026) · BMJ · doi:10.1136/bmj-2025-086886 · Cited by 47
Anson, M., Henney, A. E., Broadwell, N., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., Wilding, J. P. H., Cuthbertson, D. J., & Alam, U. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102777 · Cited by 44
Kerem, L., & Stokar, J. (2024) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2024.3812 · Cited by 45
Tang, H., Lu, Y., Donahoo, W. T., Shao, H., Shi, L., Fonseca, V. A., Guo, Y., Bian, J., & Guo, J. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0329 · Cited by 40
Pantanetti, P., Cangelosi, G., Alberti, S., Marco, S. D., Michetti, G., Cerasoli, G., Giacinti, M. D., Coacci, S., Francucci, N., Petrelli, F., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1394506 · Cited by 43
Richards, J. R., & Khalsa, S. S. (2024) · Obesity Reviews · doi:10.1111/obr.13709 · Cited by 39
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
Kushner, R. F., Ryan, D. H., Deanfield, J., Kokkinos, A., Cercato, C., Wilding, J., Burguera, B., Wu, C., Craciun, A., Pall, D., et al. (2025) · Obesity · doi:10.1002/oby.24222 · Cited by 35
Nassar, M., Misra, A., & Bloomgarden, Z. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13547 · Cited by 34
Wang, W., Davis, P. B., Qi, X., Gurney, M. E., Perry, G. L., Volkow, N. D., Kaelber, D. C., & Xu, R. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251351329 · Cited by 33
Self-citationNakhla, M., Nair, A. V., Balani, P., Ujjawal, A., Kumar, P. A., Dasari, M., Yukselen, Z., Bansal, K., Ganatra, S., & Dani, S. S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07613-w · Cited by 32
Lu, W., Wang, S., Tang, H., Yuan, T., Zuo, W., & Liu, Y. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1803 · Cited by 40
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 36
McIntyre, R. S. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2335215 · Cited by 32
El-Solh, A., Gould, E., Aibangbee, K. E., Jimerson, T., & Hartling, R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2437525 · Cited by 31
Strumila, R., Lengvenytė, A., Guillaume, S., Nobile, B., Olié, É., & Courtet, P. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.07.001 · Cited by 30
McIntyre, R. S., Rasgon, N., Goldberg, J. F., Wong, S., Le, G. H., Mansur, R. B., Rosenblat, J. D., Teopiz, K. M., & Stahl, S. M. (2025) · CNS Spectrums · doi:10.1017/s1092852925000124 · Cited by 32
Chiang, C., Song, J., Chang, Y., Osataphan, S. A., Lee, Y.-C., Chang, K.-Y., Chi, K.-Y., Chiang, C., Dua, A., Lake, L. L., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015871 · Cited by 27
Bushi, G., Khatib, M. N., Rohilla, S., Singh, M. P., Uniyal, N., Ballal, S., Bansal, P., Bhopte, K., Gupta, M., Gaidhane, A. M., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70037 · Cited by 27
Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions
Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 31
GLP-1 Receptor Agonists and Suicidality—Caution Is Needed
Salvo, F., & Faillie, J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23335 · Cited by 26
Kim, T. H., Lee, K., Park, S., Cho, H., Park, J., Jo, H., Son, Y., Kim, S., Kang, J., Smith, L., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15864 · Cited by 26
Tobaiqy, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00629-x · Cited by 25
Semaglutide for weight loss: unanswered questions
Tzoulis, P., & Baldeweg, S. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1382814 · Cited by 26
Raubenheimer, J., Myburgh, P. H., & Bhagavathula, A. S. (2024) · BMC Global and Public Health · doi:10.1186/s44263-024-00095-w · Cited by 37
Bezin, J., Bénard‐Laribière, A., Hucteau, E., Tournier, M., Montastruc, F., Pariente, A., & Faillie, J. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.103029 · Cited by 28
Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
Klausen, M. K., Knudsen, G. M., Vilsbøll, T., & Fink‐Jensen, A. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70004 · Cited by 26
Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities—Quo Vadis?
Farokhnia, M., & Leggio, L. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.4308 · Cited by 26
Stefano, R. D., Rindi, L. V., Baldini, V., Rossi, R., Pacitti, F., Jannini, E. A., & Rossi, A. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103238 · Cited by 25
Olbrich, H., Kridin, K., Zirpel, H., Hernández, G., Sadik, C. D., Gaffal, E., Thaçi, D., & Ludwig, R. J. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf346 · Cited by 22
Valentino, K., Teopiz, K. M., Cheung, W., Wong, S., Le, G. H., Rosenblat, J. D., Mansur, R. B., & McIntyre, R. S. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.02.008 · Cited by 23
Nishida, K., Chrétien, B., Dolladille, C., Ebina, T., Aleksić, B., Cabé, N., Savey, V., Onoue, T., & Yatsuya, H. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.06.011 · Cited by 28
Taipale, H. T., Taylor, M., Lähteenvuo, M., Mittendorfer-Rutz, E., Tanskanen, A. J., & Tiihonen, J. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00014-3 · Cited by 23
Breit, S., & Hubl, D. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2025.107415 · Cited by 21
The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients: A Scoping Review
Shen, M. R., Owusu-Boaitey, K. E., Holsen, L. M., & Suzuki, J. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001347 · Cited by 21
Cedirian, S., Donati, M., Rapparini, L., Pampaloni, F., Plaça, M. L., Sgarzani, R., Negosanti, L., Raschi, E., & Starace, M. V. R. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01537-5 · Cited by 25
Tang, H., Lu, Y., Donahoo, W. T., WESTEN, S. C., Chen, Y., Bian, J., & Guo, J. S. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01347 · Cited by 25
Wang, M., Yang, Z., Yan, M., Shao, L., & Xiao, S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119670 · Cited by 18
Tang, H., Zhang, B., Lu, Y., Donahoo, W. T., Ospina, N. S., Kotecha, P., Lu, Y., Tong, J., Smith, S. M., Rosenberg, E. I., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16147 · Cited by 18
Tang, H., Lu, Y., Zhang, B., Zhou, T., Zhang, D., Chen, J., Chen, Y., Asch, D. A., & Chen, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70054 · Cited by 24
Chang, Y., Hsieh, M., Ju, P., & Chang, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70175 · Cited by 20
Witaszek, T., Kłoda, K., Mastalerz–Migas, A., & Babicki, M. (2024) · Nutrients · doi:10.3390/nu16152438 · Cited by 18
McIntyre, R. S., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2430306 · Cited by 21
Semaglutide in Psychiatry—Opportunities and Challenges
Agarwal, S. M., & Hahn, M. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.2412 · Cited by 16
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Bensignor, M. O., Arslanian, S. A., & Vajravelu, M. E. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001365 · Cited by 16
Tabernacki, T., Wang, L., Kaelber, D. C., Xu, R., & Berger, N. A. (2024) · Cancers · doi:10.3390/cancers16132377 · Cited by 16
Self-citationPan, Y., Blankfield, R. P., Kaelber, D. C., & Xu, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307515 · Cited by 14
Self-citationBudin, A. J., Brown, W. A., MacCormick, A. D., Caterson, I. D., & Sumithran, P. (2025) · Obesity Reviews · doi:10.1111/obr.13927 · Cited by 18
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 13
Zhang, J., Wang, X., & Zhou, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1471615 · Cited by 13
Yeung, A. W. K., Hammerle, F. P., Behrens, S., Matin, M., Mickael, M., Litvinova, O., Parvanov, E. D., Kletečka-Pulker, M., & Atanasov, A. G. (2025) · JMIR Infodemiology · doi:10.2196/59767 · Cited by 13
The multifaceted effects of semaglutide: exploring its broad therapeutic applications
Alkhatib, M., Almasri, N., Alshwayyat, S., Almahariq, H., Hammadeh, B. M., Taimeh, Z., Alkhatib, L., Alshwayat, A. R. I., Saadeh, N. A., & Al‐kurdi, M. A. (2025) · Future Science OA · doi:10.1080/20565623.2025.2483607 · Cited by 13
Llach, C.-D., Badulescu, S., Tabassum, A., Shah, H., Gill, H., Le, G. H., Vieta, E., McIntyre, R. S., Rosenblat, J. D., & Mansur, R. B. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03261-0 · Cited by 15
Psychotropic effects of GLP-1R agonists
Bucciarelli, L. G., Cimino, V., Dell’Osso, B. M., & Fiorina, P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108036 · Cited by 13
Lin, T., Chen, Y., & Wu, C.-Y. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2616549 · Cited by 15
Ren, R., Pei, Y., Kong, L., & Shi, Y. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108932 · Cited by 13
Semaglutide - properties, action and chromatographic analysis
Wasilewska, B., & Petruczynik, A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01711-8 · Cited by 11
Glucagon-Like Peptide-1 Receptor Agonists in Psychiatry: A Pharmacoepidemiological Scoping Review
Volkow, N. D., & Xu, R. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.03.1002 · Cited by 11
Self-citationGLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
Bucci, T., Alam, U., Fauchier, G., Lochon, L., Bisson, A., Ducluzeau, P., Lip, G. Y. H., & Fauchier, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16238 · Cited by 11
Yammine, L., Grigson, P. S., Schmitz, J. M., Evans, B., & Hendershot, C. S. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00657-4 · Cited by 14
Wadden, T., Oquendo, M. A., Kushner, R. F., Cao, D., Karanikas, C. A., Kechter, A., & Murphy, M. A. (2026) · Obesity · doi:10.1002/oby.70122 · Cited by 12
Katranski, J., Liang, S., Morris, D., Suppiah, V., & Lim, C. X. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-01943-x · Cited by 10
Metadata
- Authors
- Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R.
- Affiliations
- Case Western Reserve University (US)
- National Institutes of Health (US)
- MetroHealth (US)
- Corresponding author
- Volkow, Nora D.
- Xu, Rong
- Venue
- Nature Medicine
- Published
- 2024-01
- Volume
- 30
- Issue
- 1
- Pages
- 168-176
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11034947
- OpenAlex
- W4390616108
- Cited by
- 248
- References
- 34
- Citations by year
- 2026: 72 · 2025: 91 · 2024: 84
- FWCI
- 81.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Case Comprehensive Cancer Center, Case Western Reserve University (CA043703)
- National Institute on Alcohol Abuse and Alcoholism (R01AA029831)
- National Institute on Aging (R01AG061388, R56AG062272, RF1AG076649, R01AG057557)
- National Cancer Institute (CA043703, CA2332216, P30CA043703, R25CA221718)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (DP2HD084068)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- semaglutide, suicidal ideation, GLP-1 receptor agonists, type 2 diabetes, obesity, anti-obesity drugs, drug safety, adverse drug reactions, real-world evidence
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Retrospective Studies, Anti-Obesity Agents, Overweight, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
